| June 14, 2012 | ISSUE NUMBER 255 VOL 8 |
Interview
Fixing Innovation: Lilly's CEO on the How and Why
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with Pharm Exec about his agenda as incoming chairman of PhRMA, and how to fix innovation ...Read more
Advertisement
Pharmaceutical Technology interviews EquipNet's Director of Appraisal and Valuation Services, Christopher Kinzie. Whether you're conducting an asset inventory for tax purposes, closing a facility and liquidating the equipment inside, considering a merger/acquisition, or updating your asset register for an SBA loan, check out the whitepaper and learn how professional equipment and business appraisals and valuations can help.  http://pharmtech.findpharma.com/pharmtech/Article/
ArticleStandard/Article/detail/772387 |
Diseases
Japan's Otsuka Offers Hope Against Multidrug-resistant TB
Multidrug resistant [MDR] TB accounts for more than 2 million lives per year – a death toll second only to HIV. And its prevalence is increasing, so much so that long-term progress in eliminating TB depends on beating it back with a combination of new potent drugs and preventive public health measures. That drug option has lain basically dormant for more than 40 years — until now ...Read More
Video
This Week's Episode of Pharma Four
On this week's on Pharma 4: a Washington update with correspondent Jill Wechsler, the EMA on clinical trial data fraud, PhrMA healthcare reform lobbying exposed, and Lilly CEO and incoming PhRMA head John Leichleiter on building bridges to the Japanese market ...Read More
Advertisement
The Basics of the Sunshine Act and the Implications for Your Business
Live Webcast: Tuesday, June 12, 2012 at 2:00PM EDT
Register Free at  http://www.pharmexec.com/basics |
Sales
New Report on Sales Rep Visits and Physician Prescribing Habits
Jennnifer Ringler talks to ZS Associates' Pratap Khedkar, co-author of a new study that suggests physicians who see fewer reps are slower when it comes to dropping 'black-box' drugs — and at adopting promising new medications ...Read more
 Regulatory
FDA Feels the Pinch of House Funding Cuts
The House Appropriations Committee's 2013 Agriculture Appropriations, which sets proposed spending levels for FDA as well as for other programs, calls for nearly $ 2.5 billion in discretionary funding, a cut of $16.3 million, or 0.7%, below last year's level ...Read more
|
|
|
 // Merck & Co. appointed Michael Holston as its new Chief Ethics and Compliance Officer, replacing Richard Bowles, who is retiring. Mr Holston takes up his new position on June 25, coming from Hewlett-Packard. // Cavan M. Redmond, formerly Group President, Animal Health, Consumer Health and Corporate Strategy at Pfizer, joined WebMD Health Corp. (New York, NY) as its new CEO. // David Jaworski joined Lachman Consultants (Westbury, NY) as a Director in its Compliance Practice. Mr Jaworski comes FDA, where he most recently served as Acting Branch Chief, Domestic Compliance Branch, Division of Domestic Drug Quality in the Office of Manufacturing and Product Quality/Office of Compliance/CDER. |
|
|
|
Advertisement
Utilization of Rasch Measurement Models for Assessing Validity: A Mixed Methods Approach
On-Demand Webcast
 Click here |
|
|
|
|
|
 |
|
|
 |
|
 |
|
 |
|
 |
Do you believe the pharma industry has become more transparent overall?
|
|
|
|
